Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Liver Diseases

Free Subscription Articles published in J Gastroenterol Hepatol Retrieve available abstracts of 202 articles: HTML format

Single Articles

June 2022
1. LIU H, Yang XL, Dong ZR, Chen ZQ, et al
   Clinical Benefits of Direct-acting Antivirals Therapy in Hepatitis C Virus Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
   J Gastroenterol Hepatol. 2022 Jun 20. doi: 10.1111/jgh.15915.
   PubMed     Abstract available
   
   
   
2. WONG YJ, Li J, Liu C, Chen Z, et al
   CHESS-ALARM score to stratify decompensation risk in compensated advanced chronic liver disease patients: An international multicenter study.
   J Gastroenterol Hepatol. 2022;37:1043-1051.
   PubMed     Abstract available
   
   
   May 2022
3. DUNN W, Song X, Koestler D, Grdinovac K, et al
   Patients with type 2 diabetes and elevated fibrosis-4 are under-referred to hepatology and have unrecognized hepatic decompensation.
   J Gastroenterol Hepatol. 2022 May 25. doi: 10.1111/jgh.15900.
   PubMed     Abstract available
   
   
   
4. CHAN SL, Wong N, Lam WKJ, Kuang M, et al
   Personalized treatment for hepatocellular carcinoma: Current status and Future perspectives.
   J Gastroenterol Hepatol. 2022 May 15. doi: 10.1111/jgh.15889.
   PubMed     Abstract available
   
   
   
5. TENG PC, Agopian VG, Lin TY, You S, et al
   Circulating tumor cells: a step toward precision medicine in hepatocellular carcinoma.
   J Gastroenterol Hepatol. 2022 May 11. doi: 10.1111/jgh.15886.
   PubMed     Abstract available
   
   
   
6. CHOI AY, Kolb J, Shah S, Chahine A, et al
   Endoscopic ultrasound-guided portal pressure gradient with liver biopsy: 6 years of endo-hepatology in practice.
   J Gastroenterol Hepatol. 2022 May 5. doi: 10.1111/jgh.15875.
   PubMed     Abstract available
   
   
   
7. WANG X, Gao X, Wu R, Chi X, et al
   Serum qAnti-HBc combined with ALT and HBsAg predicts significant hepatic inflammation in HBeAg-positive immune active patients.
   J Gastroenterol Hepatol. 2022 May 4. doi: 10.1111/jgh.15881.
   PubMed     Abstract available
   
   
   April 2022
8. SHINKAI K, Sakamori R, Yamada R, Tahata Y, et al
   Prognostic impact of worsening of esophageal varices after balloon-occluded retrograde transvenous obliteration.
   J Gastroenterol Hepatol. 2022 Apr 17. doi: 10.1111/jgh.15853.
   PubMed     Abstract available
   
   
   
9. SATO M, Kobayashi T, Soroida Y, Tanaka T, et al
   Development of novel deep multimodal representation learning-based model for the differentiation of liver tumors on B-mode ultrasound images.
   J Gastroenterol Hepatol. 2022;37:678-684.
   PubMed     Abstract available
   
   
   
10. SASAKI Y, Abe Y, Nishise S, Yagi M, et al
    Low serum pancreatic amylase levels as a novel latent risk factor for colorectal adenoma in non-alcohol drinkers.
    J Gastroenterol Hepatol. 2022;37:660-668.
    PubMed     Abstract available
    
    
    March 2022
11. LEUNG HH, Puspanathan P, Chan AW, Mustapha NRN, et al
    Reliability of the Nonalcoholic Steatohepatitis Clinical Research Network and Steatosis Activity Fibrosis histological scoring systems.
    J Gastroenterol Hepatol. 2022 Mar 31. doi: 10.1111/jgh.15843.
    PubMed     Abstract available
    
    
    
12. HUANG X, Zhu L, Wang L, Huang W, et al
    YTHDF1 promotes intrahepatic cholangiocarcinoma progression via regulating EGFR mRNA translation.
    J Gastroenterol Hepatol. 2022 Mar 1. doi: 10.1111/jgh.15816.
    PubMed     Abstract available
    
    
    
13. OGAWA Y, Nakahara T, Ono M, Kawaguchi T, et al
    Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease.
    J Gastroenterol Hepatol. 2022;37:592-599.
    PubMed     Abstract available
    
    
    
14. HUSSAIN I, Wong YJ, Lohan R, Lin S, et al
    Does preemptive transjugular intrahepatic portosystemic shunt improve survival after acute variceal bleeding? Systematic review, meta-analysis, and trial sequential analysis of randomized trials.
    J Gastroenterol Hepatol. 2022;37:455-463.
    PubMed     Abstract available
    
    
    February 2022
15. LIU Y, Liu S, Huang J, Zhu Y, et al
    Validation of five hepatic steatosis algorithms in metabolic- associated fatty liver disease: a population based study.
    J Gastroenterol Hepatol. 2022 Feb 16. doi: 10.1111/jgh.15799.
    PubMed     Abstract available
    
    
    
16. MUNDADA K, Goel A, Paliwal VK, Singh TP, et al
    Short course of low-dose pregabalin is effective for the treatment of restless leg syndrome in patients with cirrhosis: A pilot study.
    J Gastroenterol Hepatol. 2022 Feb 16. doi: 10.1111/jgh.15803.
    PubMed     Abstract available
    
    
    
17. KEMP W, Clayton-Chubb D, Majeed A, Glenister KM, et al
    Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study.
    J Gastroenterol Hepatol. 2022;37:395-403.
    PubMed     Abstract available
    
    
    
18. BE KH, Zorron Cheng Tao Pu L, Apostolov R, Vaughan R, et al
    Gastrointestinal: Gastric variceal coil migration: A rare entity in endoscopy.
    J Gastroenterol Hepatol. 2022;37:281.
    PubMed    
    
    
    January 2022
19. YUAN BH, Li RH, Huo RR, Li MJ, et al
    Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis.
    J Gastroenterol Hepatol. 2022 Jan 26. doi: 10.1111/jgh.15783.
    PubMed     Abstract available
    
    
    
20. CHAN WK, Tan SS, Chan SP, Lee YY, et al
    The Malaysian Society of Gastroenterology and Hepatology Consensus Statement on Metabolic Dysfunction-Associated Fatty Liver Disease.
    J Gastroenterol Hepatol. 2022 Jan 25. doi: 10.1111/jgh.15787.
    PubMed     Abstract available
    
    
    
21. MOLLER S, Henriksen JH, Sjostedt S, Bendtsen F, et al
    Determination of hepatic clearance by derivations of the indocyanine green retention test in cirrhosis.
    J Gastroenterol Hepatol. 2022 Jan 11. doi: 10.1111/jgh.15778.
    PubMed     Abstract available
    
    
    
22. YU J
    The functional role and translational potential of gut microbiota and microbial metabolites in liver diseases.
    J Gastroenterol Hepatol. 2022;37:5-6.
    PubMed    
    
    
    
23. LI M, Rajani C, Zheng X, Jia W, et al
    The microbial metabolome in metabolic-associated fatty liver disease.
    J Gastroenterol Hepatol. 2022;37:15-23.
    PubMed     Abstract available
    
    
    
24. SUK KT, Koh H
    New perspective on fecal microbiota transplantation in liver diseases.
    J Gastroenterol Hepatol. 2022;37:24-33.
    PubMed     Abstract available
    
    
    
25. PAN Y, Zhang X
    Diet and gut microbiome in fatty liver and its associated liver cancer.
    J Gastroenterol Hepatol. 2022;37:7-14.
    PubMed     Abstract available
    
    
    December 2021
26. AHN HS, Kim HJ, Kang TU, Park SM, et al
    Cholecystectomy reduces the risk of cholangiocarcinoma in patients with complicated gallstones, but has negligible effect on hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2021 Dec 14. doi: 10.1111/jgh.15759.
    PubMed     Abstract available
    
    
    
27. KERR CJ, Waterworth SP, Brodie D, Sandercock GRH, et al
    The associations between physical activity intensity, cardiorespiratory fitness, and non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:3508-3514.
    PubMed     Abstract available
    
    
    
28. PAN J, Cen L, Zhou T, Yu M, et al
    Insulin-like growth factor binding protein 1 ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:3438-3447.
    PubMed     Abstract available
    
    
    
29. HUANG H, Hou J, Liu K, Liu Q, et al
    RAB27A-dependent release of exosomes by liver cancer stem cells induces Nanog expression in their differentiated progenies and confers regorafenib resistance.
    J Gastroenterol Hepatol. 2021;36:3429-3437.
    PubMed     Abstract available
    
    
    
30. SATO Y, Yoneda A, Shimizu F, Nishimura M, et al
    Resolution of fibrosis by siRNA HSP47 in vitamin A-coupled liposomes induces regeneration of chronically injured livers.
    J Gastroenterol Hepatol. 2021;36:3418-3428.
    PubMed     Abstract available
    
    
    
31. ZHU Z, Yin J, Dawsey SM, Liu B, et al
    Association between serum ferritin, incident primary liver cancer, and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: A nested case-control study.
    J Gastroenterol Hepatol. 2021;36:3410-3417.
    PubMed     Abstract available
    
    
    November 2021
32. GAZELAKIS K, Mendis S, Wang S, Wong S, et al
    Hepatobiliary and Pancreatic: Liver lesions in cirrhosis: When to biopsy?
    J Gastroenterol Hepatol. 2021 Nov 22. doi: 10.1111/jgh.15735.
    PubMed    
    
    
    
33. KIM BH, Yu SJ, Kang W, Cho SB, et al
    Expert Consensus on the Management of Adverse Events in Patients Receiving Lenvatinib for Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2021 Nov 1. doi: 10.1111/jgh.15727.
    PubMed     Abstract available
    
    
    
34. POTOUPNI V, Georgiadou M, Chatzigriva E, Polychronidou G, et al
    Circulating tumor necrosis factor-alpha levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis.
    J Gastroenterol Hepatol. 2021;36:3002-3014.
    PubMed     Abstract available
    
    
    
35. LEE S, Kim KW, Lee J, Park T, et al
    Visceral adiposity as a risk factor for lean non-alcoholic fatty liver disease in potential living liver donors.
    J Gastroenterol Hepatol. 2021;36:3212-3218.
    PubMed     Abstract available
    
    
    
36. KUCHAY MS, Choudhary NS, Gagneja S, Mathew A, et al
    Low skeletal muscle mass is associated with liver fibrosis in individuals with type 2 diabetes and nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:3204-3211.
    PubMed     Abstract available
    
    
    October 2021
37. LE TV, Dinh NBT, Dang MT, Phan NCL, et al
    THE EFFECTS OF AUTOPHAGY INHIBITION BY CHLOROQUINE ON HEPATIC STELLATE CELL ACTIVATION IN CCl4 -INDUCED ACUTE LIVER INJURY MOUSE MODEL.
    J Gastroenterol Hepatol. 2021 Oct 28. doi: 10.1111/jgh.15726.
    PubMed     Abstract available
    
    
    
38. CHANG WI, Kim BH, Kim YJ, Yoon JH, et al
    The role of radiotherapy in Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma treated with sorafenib.
    J Gastroenterol Hepatol. 2021 Oct 24. doi: 10.1111/jgh.15722.
    PubMed     Abstract available
    
    
    
39. NAKATSU G
    Toward a postbiotic era of microbiome science: opportunities to advance immunotherapies for hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2021 Oct 19. doi: 10.1111/jgh.15715.
    PubMed     Abstract available
    
    
    
40. CHEN T, Zhou K, Sun T, Sang C, et al
    Bile acid glycine:taurine ratios predict the progression of chronic liver disease.
    J Gastroenterol Hepatol. 2021 Oct 16. doi: 10.1111/jgh.15709.
    PubMed     Abstract available
    
    
    
41. HUO TI, Ho SY, Liao JI
    Improved patient survival in hepatitis C virus-related hepatocellular carcinoma: Do direct-acting antivirals play a role?
    J Gastroenterol Hepatol. 2021 Oct 15. doi: 10.1111/jgh.15707.
    PubMed    
    
    
    
42. YIM HJ, Kim W, Ahn SH, Jung YK, et al
    Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients.
    J Gastroenterol Hepatol. 2021 Oct 15. doi: 10.1111/jgh.15710.
    PubMed     Abstract available
    
    
    
43. OGAWA E, Kawano A, Ooho A, Furusyo N, et al
    Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for HCV infection.
    J Gastroenterol Hepatol. 2021 Oct 7. doi: 10.1111/jgh.15703.
    PubMed     Abstract available
    
    
    
44. TAMAKI N, Kurosaki M, Takahashi Y, Itakura Y, et al
    Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease.
    J Gastroenterol Hepatol. 2021;36:2960-2966.
    PubMed     Abstract available
    
    
    
45. CHEN TP, Lin WY, Chiang CH, Shen TH, et al
    Metabolically healthy obesity and risk of non-alcoholic fatty liver disease severity independent of visceral fat.
    J Gastroenterol Hepatol. 2021;36:2903-2910.
    PubMed     Abstract available
    
    
    
46. HU HT, Wang W, Chen LD, Ruan SM, et al
    Artificial intelligence assists identifying malignant versus benign liver lesions using contrast-enhanced ultrasound.
    J Gastroenterol Hepatol. 2021;36:2875-2883.
    PubMed     Abstract available
    
    
    
47. RODRIGUEZ-ANTONIO I, Lopez-Sanchez GN, Uribe M, Chavez-Tapia NC, et al
    Role of the inflammasome, gasdermin D, and pyroptosis in non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021;36:2720-2727.
    PubMed     Abstract available
    
    
    
48. WANG Y, Liu Y
    Gut-liver-axis: Barrier function of liver sinusoidal endothelial cell.
    J Gastroenterol Hepatol. 2021;36:2706-2714.
    PubMed     Abstract available
    
    
    September 2021
49. LI R, Ong Q, Wong CC, Chu ES, et al
    O-GlcNAcylation inhibits hepatic stellate cell activation.
    J Gastroenterol Hepatol. 2021 Sep 21. doi: 10.1111/jgh.15690.
    PubMed     Abstract available
    
    
    
50. LOCKART I, Hajarizadeh B, Buckley N, Davison S, et al
    All cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy.
    J Gastroenterol Hepatol. 2021 Sep 14. doi: 10.1111/jgh.15687.
    PubMed     Abstract available
    
    
    
51. YADA S, Sasaki S, Tokuno K, Yamashita Y, et al
    Hepatobiliary and Pancreatic: Extramammary Paget disease of the esophagus.
    J Gastroenterol Hepatol. 2021 Sep 2. doi: 10.1111/jgh.15665.
    PubMed    
    
    
    
52. PENNISI G, Di Marco V, Buscemi C, Mazzola G, et al
    Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population.
    J Gastroenterol Hepatol. 2021;36:2389-2396.
    PubMed     Abstract available
    
    
    
53. CHEN D, Zeng R, Teng G, Cai C, et al
    Menstrual blood-derived mesenchymal stem cells attenuate inflammation and improve the mortality of acute liver failure combining with A2AR agonist in mice.
    J Gastroenterol Hepatol. 2021;36:2619-2627.
    PubMed     Abstract available
    
    
    August 2021
54. ZHAO D, Xia L, Geng W, Xu D, et al
    Metformin suppresses IL-22 induced hepatocellular carcinoma by upregulating Hippo signaling pathway.
    J Gastroenterol Hepatol. 2021 Aug 25. doi: 10.1111/jgh.15674.
    PubMed     Abstract available
    
    
    
55. EMORI T, Nuta J, Kawaji Y, Tamura T, et al
    Value of contrast-enhanced harmonic endoscopic ultrasound for diagnosing hepatic metastases of pancreatic cancer: a prospective study.
    J Gastroenterol Hepatol. 2021 Aug 16. doi: 10.1111/jgh.15661.
    PubMed     Abstract available
    
    
    
56. OGAWA E, Nakamuta M, Furusyo N, Kajiwara E, et al
    Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by DAAs.
    J Gastroenterol Hepatol. 2021 Aug 9. doi: 10.1111/jgh.15659.
    PubMed     Abstract available
    
    
    
57. UENO M, Mano T, Kayahara T, Mizuno M, et al
    Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding: It's time to step forward.
    J Gastroenterol Hepatol. 2021 Aug 8. doi: 10.1111/jgh.15652.
    PubMed    
    
    
    
58. CHEN M, Hu G, Zhou X, Peng Z, et al
    Hsa_circ_0016788 regulates glycolysis and proliferation via miR-506-3p/PARP14 axis of hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2021 Aug 2. doi: 10.1111/jgh.15635.
    PubMed     Abstract available
    
    
    
59. TAHER MK, Crispo JAG, Fortin Y, Moog R, et al
    Systemic quinolones and risk of acute liver failure III: A nested case-control study using a US electronic health records database.
    J Gastroenterol Hepatol. 2021;36:2307-2314.
    PubMed     Abstract available
    
    
    
60. CHEN H, Johnston A, Palmer A, Mickenbecker M, et al
    Too little, too late: Palliation and end-stage liver disease.
    J Gastroenterol Hepatol. 2021;36:2303-2306.
    PubMed     Abstract available
    
    
    July 2021
61. MAK J, Chan SM, Siu B, Lai J, et al
    Hepatobiliary and Pancreatic: A tree in the liver.
    J Gastroenterol Hepatol. 2021 Jul 27. doi: 10.1111/jgh.15623.
    PubMed    
    
    
    
62. ATTEBERRY P, Biederman B, Jesudian A, Lucero C, et al
    Mortality, Sepsis, and Organ Failure in Hospitalized Patients with Cirrhosis Vary by Type of Infection.
    J Gastroenterol Hepatol. 2021 Jul 22. doi: 10.1111/jgh.15633.
    PubMed     Abstract available
    
    
    
63. SHI M, Sheng L, Lian M, Miao Q, et al
    Efficacy and safety of rifampicin in patients with persistent hepatocellular secretory failure.
    J Gastroenterol Hepatol. 2021 Jul 19. doi: 10.1111/jgh.15629.
    PubMed     Abstract available
    
    
    
64. WU L, Huang XQ, Li N, Xie C, et al
    An MRI Modality for Non-invasively Distinguishing Progression of Liver Fibrosis by Visualizing Hepatic Platelet-Derived Growth Factor Receptor-Beta Expression in Mice.
    J Gastroenterol Hepatol. 2021 Jul 19. doi: 10.1111/jgh.15628.
    PubMed     Abstract available
    
    
    
65. KRIGE J, Jonas E, Spence R, Bernon M, et al
    Letter to the editor: The complexities of predicting outcome in cirrhotic patients with acute variceal bleeding.
    J Gastroenterol Hepatol. 2021 Jul 12. doi: 10.1111/jgh.15622.
    PubMed    
    
    
    
66. ITO T, Hanafusa N, Soneda N, Isoai A, et al
    Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) against cirrhotic ascites in comparison with malignancy-related ascites.
    J Gastroenterol Hepatol. 2021 Jul 11. doi: 10.1111/jgh.15620.
    PubMed     Abstract available
    
    
    
67. LIU CH, Ampuero J, Pavlides M, Wong VW, et al
    Simple non-invasive scoring systems and histological scores in predicting mortality in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2021;36:1754-1768.
    PubMed     Abstract available
    
    
    
68. KANG HT, Jang K, Jun DW, Yoon EL, et al
    Macro-encapsulation of mesenchymal stem cells in acute and chronic liver injury animal models.
    J Gastroenterol Hepatol. 2021;36:1997-2007.
    PubMed     Abstract available
    
    
    
69. KULKARNI AV, Anand L, Vyas AK, Premkumar M, et al
    Omega-3 fatty acid lipid emulsions are safe and effective in reducing endotoxemia and sepsis in acute-on-chronic liver failure: An open-label randomized controlled trial.
    J Gastroenterol Hepatol. 2021;36:1953-1961.
    PubMed     Abstract available
    
    
    
70. NISHIKAWA M, Kinoshita M, Morimoto Y, Ishikiriyama T, et al
    Lipopolysaccharide preconditioning reduces liver metastasis of Colon26 cells by enhancing antitumor activity of natural killer cells and natural killer T cells in murine liver.
    J Gastroenterol Hepatol. 2021;36:1889-1898.
    PubMed     Abstract available
    
    
    
71. YAMAMOTO K, Ikeya T, Okuyama S, Fukuda K, et al
    The association between non-alcoholic fatty liver disease (with or without metabolic syndrome) and extrahepatic cancer development.
    J Gastroenterol Hepatol. 2021;36:1971-1978.
    PubMed     Abstract available
    
    
    June 2021
72. COUPER MR, Chennapragada M, Magoffin A
    Hepatobiliary and Pancreatic: A rare peribiliary lesion.
    J Gastroenterol Hepatol. 2021 Jun 29. doi: 10.1111/jgh.15556.
    PubMed    
    
    
    
73. ZULLO A, Soncini M, Bucci C, Marmo R, et al
    Clinical outcomes in cirrhotics with variceal or nonvariceal gastrointestinal bleeding: a prospective, multicenter cohort study.
    J Gastroenterol Hepatol. 2021 Jun 29. doi: 10.1111/jgh.15601.
    PubMed     Abstract available
    
    
    
74. HO SY, Liu PH, Hsu CY, Ko CC, et al
    Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    J Gastroenterol Hepatol. 2021 Jun 22. doi: 10.1111/jgh.15593.
    PubMed     Abstract available
    
    
    
75. PHRUEKSOTSAI S, Pinyopornpanish K, Euathrongchit J, Leerapun A, et al
    Dapagliflozin reduces hepatic and visceral fat in type-2 diabetes patients with non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021 Jun 15. doi: 10.1111/jgh.15580.
    PubMed     Abstract available
    
    
    
76. FAJARDO J, Nunez E, Szafranska J, Poca M, et al
    We report a patient who presented intrahepatic cholangitis and cholecystitis after SARS-CoV-2 infection.
    J Gastroenterol Hepatol. 2021 Jun 9. doi: 10.1111/jgh.15537.
    PubMed    
    
    
    
77. CHUN HS, Lee JS, Lee HW, Kim BK, et al
    Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes.
    J Gastroenterol Hepatol. 2021;36:1703-1713.
    PubMed     Abstract available
    
    
    
78. HASSANI ZADEH S, Mansoori A, Hosseinzadeh M
    Relationship between dietary patterns and non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2021;36:1470-1478.
    PubMed     Abstract available
    
    
    
79. AHADI M, Molooghi K, Masoudifar N, Namdar AB, et al
    A review of non-alcoholic fatty liver disease in non-obese and lean individuals.
    J Gastroenterol Hepatol. 2021;36:1497-1507.
    PubMed     Abstract available
    
    
    
80. RHODES FA, Trembling P, Panovska-Griffiths J, Tanwar S, et al
    Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
    J Gastroenterol Hepatol. 2021;36:1435-1449.
    PubMed     Abstract available
    
    
    
81. LV T, Chen S, Li M, Zhang D, et al
    Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2021;36:1423-1434.
    PubMed     Abstract available
    
    
    
82. LIU D, Shen Y, Zhang R, Xun J, et al
    Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
    J Gastroenterol Hepatol. 2021;36:1670-1678.
    PubMed     Abstract available
    
    
    
83. HUANG Y, Huang F, Yang L, Hu W, et al
    Development and validation of a radiomics signature as a non-invasive complementary predictor of gastroesophageal varices and high-risk varices in compensated advanced chronic liver disease: A multicenter study.
    J Gastroenterol Hepatol. 2021;36:1562-1570.
    PubMed     Abstract available
    
    
    
84. YIP TC, Wong VW, Wong GL
    Liver-heart connection in diabetes mellitus.
    J Gastroenterol Hepatol. 2021;36:1385-1386.
    PubMed    
    
    
    May 2021
85. ZHOU J, Wang C, Chen Z
    Hepatobiliary and Pancreatic: Castleman disease of the pancreas diagnosed by endoscopic ultrasound.
    J Gastroenterol Hepatol. 2021 May 31. doi: 10.1111/jgh.15520.
    PubMed    
    
    
    
86. KANEKO S, Kurosaki M, Inada K, Kirino S, et al
    Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients.
    J Gastroenterol Hepatol. 2021 May 31. doi: 10.1111/jgh.15563.
    PubMed     Abstract available
    
    
    
87. AGARWAL S, Sharma S, Kumar M, Venishetty S, et al
    Development of a machine learning model to predict bleed in esophageal varices in compensated advanced chronic liver disease: A proof of concept.
    J Gastroenterol Hepatol. 2021 May 28. doi: 10.1111/jgh.15560.
    PubMed     Abstract available
    
    
    
88. MA HL, Chen SD, Zheng KI, Yu Y, et al
    The TA allele of rs2070673 in the CYP2E1 gene is associated with lobular inflammation and nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2021 May 24. doi: 10.1111/jgh.15554.
    PubMed     Abstract available
    
    
    
89. TAK KY, Jang B, Lee SK, Nam HC, et al
    The prognostic role of M2BPGi compared with the HAP score in hepatocellular carcinoma patients receiving transarterial treatment.
    J Gastroenterol Hepatol. 2021 May 24. doi: 10.1111/jgh.15553.
    PubMed     Abstract available
    
    
    
90. ZHAO JA, Nie W, Dong L, Liu W, et al
    A curcumin analogue GL63 inhibits the malignant behaviors of hepatocellular carcinoma by inactivating the JAK2/STAT3 signaling pathway via the circZNF83/miR-324-5p/CDK16 axis.
    J Gastroenterol Hepatol. 2021 May 12. doi: 10.1111/jgh.15545.
    PubMed     Abstract available
    
    
    
91. CHANG H, Li J, Luo Y, Wu B, et al
    TFB2M activates aerobic glycolysis in hepatocellular carcinoma cells through the NAD(+) /SIRT3/HIF-1alpha signaling.
    J Gastroenterol Hepatol. 2021 May 12. doi: 10.1111/jgh.15548.
    PubMed     Abstract available
    
    
    
92. YANG C, Liu J, Shi Q, Huang S, et al
    Effect of splenectomy on the outcomes in patients with cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    J Gastroenterol Hepatol. 2021 May 11. doi: 10.1111/jgh.15543.
    PubMed     Abstract available
    
    
    
93. XIE JM, Liu JH, Sun YH, Li W, et al
    Hepatobiliary and Pancreatic: Endoscopic resection of biliary ductal tumour.
    J Gastroenterol Hepatol. 2021 May 9. doi: 10.1111/jgh.15518.
    PubMed    
    
    
    
94. HSU WF, Tsai PC, Chen CY, Tseng KC, et al
    Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (T-COACH).
    J Gastroenterol Hepatol. 2021 May 7. doi: 10.1111/jgh.15538.
    PubMed     Abstract available
    
    
    
95. CHEN Z, Jiang H, Wang Y, Liang R, et al
    Three-day Postoperative Antibiotics Reduces Post-hepatectomy Infection Rate in HBV-related Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2021 May 4. doi: 10.1111/jgh.15528.
    PubMed     Abstract available
    
    
    
96. ANAND A, Elhence A, Vaishnav M, Singh AA, et al
    FibroScan-aspartate aminotransferase score in an Asian cohort of non-alcoholic fatty liver disease and its utility in predicting histological resolution with bariatric surgery.
    J Gastroenterol Hepatol. 2021;36:1309-1316.
    PubMed     Abstract available
    
    
    
97. LI X, Qin P, Cao L, Lou Y, et al
    Dose-response association of the ZJU index and fatty liver disease risk: A large cohort in China.
    J Gastroenterol Hepatol. 2021;36:1326-1333.
    PubMed     Abstract available
    
    
    
98. TANDON R, Froghi S
    Artificial liver support systems.
    J Gastroenterol Hepatol. 2021;36:1164-1179.
    PubMed     Abstract available
    
    
    April 2021
99. PUDIPEDDI A, Han J, Leong R
    Hepatobiliary and Pancreatic: Right upper quadrant pain and positive Murphy's sign.
    J Gastroenterol Hepatol. 2021 Apr 29. doi: 10.1111/jgh.15510.
    PubMed    
    
    
    
100. KAPURIA D, Bollipo S, Rabiee A, Ben-Yakov G, et al
     Roadmap to resuming care for liver diseases after coronavirus disease-2019.
     J Gastroenterol Hepatol. 2021;36:885-892.
     PubMed     Abstract available
     
     
     
101. CHRYSAVGIS L, Papatheodoridi AM, Chatzigeorgiou A, Cholongitas E, et al
     The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
     J Gastroenterol Hepatol. 2021;36:893-909.
     PubMed     Abstract available
     
     
     
102. SHIGEFUKU R, Iwasa M, Eguchi A, Tamai Y, et al
     Serum copeptin level is a biomarker associated with ascites retention and the formation of a portosystemic shunt in chronic liver disease.
     J Gastroenterol Hepatol. 2021;36:1006-1014.
     PubMed     Abstract available
     
     
     March 2021
103. IWAKI M, Kessoku T, Ozaki A, Kasai Y, et al
     Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease.
     J Gastroenterol Hepatol. 2021 Mar 11. doi: 10.1111/jgh.15487.
     PubMed     Abstract available
     
     
     
104. SHARMA C, Cococcia S, Ellis N, Parkes J, et al
     Systematic review: Accuracy of The Enhanced Liver Fibrosis Test for diagnosing advanced liver fibrosis and cirrhosis.
     J Gastroenterol Hepatol. 2021 Mar 5. doi: 10.1111/jgh.15482.
     PubMed     Abstract available
     
     
     
105. MOU H, Yang QA, Yu L, Wang T, et al
     PD-L1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics.
     J Gastroenterol Hepatol. 2021 Mar 3. doi: 10.1111/jgh.15475.
     PubMed     Abstract available
     
     
     
106. SATO M, Tateishi R, Yatomi Y, Koike K, et al
     Artificial intelligence in the diagnosis and management of hepatocellular carcinoma.
     J Gastroenterol Hepatol. 2021;36:551-560.
     PubMed     Abstract available
     
     
     
107. SU TH, Wu CH, Kao JH
     Artificial intelligence in precision medicine in hepatology.
     J Gastroenterol Hepatol. 2021;36:569-580.
     PubMed     Abstract available
     
     
     
108. SUNG YS, Park B, Park HJ, Lee SS, et al
     Radiomics and deep learning in liver diseases.
     J Gastroenterol Hepatol. 2021;36:561-568.
     PubMed     Abstract available
     
     
     
109. WONG GL, Yuen PC, Ma AJ, Chan AW, et al
     Artificial intelligence in prediction of non-alcoholic fatty liver disease and fibrosis.
     J Gastroenterol Hepatol. 2021;36:543-550.
     PubMed     Abstract available
     
     
     
110. LEE HW, Sung JJY, Ahn SH
     Artificial intelligence in liver disease.
     J Gastroenterol Hepatol. 2021;36:539-542.
     PubMed     Abstract available
     
     
     February 2021
111. WEST J, Gow PJ, Testro A, Chapman B, et al
     Exercise physiology in cirrhosis and the potential benefits of exercise interventions - a review.
     J Gastroenterol Hepatol. 2021 Feb 27. doi: 10.1111/jgh.15474.
     PubMed     Abstract available
     
     
     
112. HEO YJ, Choi SE, Lee N, Jeon JY, et al
     Visfatin exacerbates hepatic inflammation and fibrosis in a methionine-choline-deficient diet mouse model.
     J Gastroenterol Hepatol. 2021 Feb 18. doi: 10.1111/jgh.15465.
     PubMed     Abstract available
     
     
     
113. JEONG Y, Lee KJ, Lee SJ, Shin YM, et al
     Radiofrequency ablation versus stereotactic body radiation therapy for small (
     J Gastroenterol Hepatol. 2021 Feb 17. doi: 10.1111/jgh.15442.
     PubMed     Abstract available
     
     
     
114. WU Y, Xiang Q, Lv X, Xiang X, et al
     C2orf40 inhibits hepatocellular carcinoma through UBR5-dependent or p53-independent mechanisms.
     J Gastroenterol Hepatol. 2021 Feb 12. doi: 10.1111/jgh.15441.
     PubMed     Abstract available
     
     
     
115. JIA Z, Zhang H, Li N
     Evaluation of clinical outcomes of radiofrequency ablation and surgical resection for hepatocellular carcinoma conforming to the Milan criteria: A systematic review and meta-analysis of recent randomized controlled trials.
     J Gastroenterol Hepatol. 2021 Feb 10. doi: 10.1111/jgh.15440.
     PubMed     Abstract available
     
     
     
116. KIM JH, Park SW, Jung JH, Park DH, et al
     Bedside Risk-Scoring Model for Predicting 6-Week Mortality in Cirrhotic Patients Undergoing Endoscopic Band Ligation for Acute Variceal Bleeding.
     J Gastroenterol Hepatol. 2021 Feb 4. doi: 10.1111/jgh.15426.
     PubMed     Abstract available
     
     
     
117. VADARLIS A, Antza C, Bakaloudi DR, Doundoulakis I, et al
     Systematic review with meta-analysis: The effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease.
     J Gastroenterol Hepatol. 2021;36:311-319.
     PubMed     Abstract available
     
     
     January 2021
118. TENG CF, Wang T, Shih FY, Shyu WC, et al
     Therapeutic Efficacy of Dendritic Cell Vaccine Combined with Programmed Death 1 Inhibitor for Hepatocellular Carcinoma.
     J Gastroenterol Hepatol. 2021 Jan 19. doi: 10.1111/jgh.15398.
     PubMed     Abstract available
     
     
     
119. YOO BH, Kim SH, Baek YJ, Yeom JS, et al
     Hepatobiliary and Pancreatic: Liver abscess not responding to drainage and antibiotics.
     J Gastroenterol Hepatol. 2021 Jan 17. doi: 10.1111/jgh.15383.
     PubMed    
     
     
     
120. YOSHINO K, Taura K, Iwaisako K, Masano Y, et al
     A novel mouse model for cholestasis-induced liver fibrosis resolution by cholecystojejunostomy.
     J Gastroenterol Hepatol. 2021 Jan 15. doi: 10.1111/jgh.15406.
     PubMed     Abstract available
     
     
     
121. DING ZN, Dong ZR, Chen ZQ, Yang YF, et al
     Effects of HIF-1alpha and HIF-2alpha overexpression on hepatocellular carcinoma survival: A systematic review with meta-analysis.
     J Gastroenterol Hepatol. 2021 Jan 4. doi: 10.1111/jgh.15395.
     PubMed     Abstract available
     
     
     
122. YI F, Guo X, Wang L, Xu X, et al
     Spontaneous splenorenal shunt may decrease the long-term survival of liver cirrhosis by compromising liver volume.
     J Gastroenterol Hepatol. 2021 Jan 3. doi: 10.1111/jgh.15386.
     PubMed     Abstract available
     
     
     
123. GAO F, Zheng KI, Wang XB, Yan HD, et al
     Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients.
     J Gastroenterol Hepatol. 2021;36:204-207.
     PubMed     Abstract available
     
     
     
124. LUM JHM, Cheah MCC, Leow WQ, Wan WK, et al
     Clinical profile of non-alcoholic fatty liver disease in nonobese patients.
     J Gastroenterol Hepatol. 2021;36:257-261.
     PubMed     Abstract available
     
     
     
125. GRONBAEK H, Moller HJ, Saliba F, Zeuzem S, et al
     Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute-on-chronic liver failure and acute decompensation.
     J Gastroenterol Hepatol. 2021;36:240-248.
     PubMed     Abstract available
     
     
     December 2020
126. YAMAOKA K, Kodama K, Hiramatsu A, Ando Y, et al
     Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma.
     J Gastroenterol Hepatol. 2020 Dec 16. doi: 10.1111/jgh.15377.
     PubMed     Abstract available
     
     
     
127. MOCAN T, Nenu I, Craciun R, Sparchez Z, et al
     Treatment of hepatitis C virus infection in patients with hepatocellular carcinoma: truth or dare?
     J Gastroenterol Hepatol. 2020 Dec 16. doi: 10.1111/jgh.15376.
     PubMed     Abstract available
     
     
     
128. TERRA C, Perez R
     Albumin for cirrhotic patients with infections unrelated to spontaneous bacterial peritonitis: A still no answered question.
     J Gastroenterol Hepatol. 2020;35:2290-2291.
     PubMed    
     
     
     November 2020
129. KIM DY, Lee HW, Kang W, Kim GM, et al
     Metabolic activity assessment by 18F-FDG PET in patients with hepatocellular carcinoma undergoing Yttrium-90 TARE.
     J Gastroenterol Hepatol. 2020 Nov 23. doi: 10.1111/jgh.15357.
     PubMed     Abstract available
     
     
     
130. KIM KJ, Lee HW, Seong J
     Combination therapy with anti-TIM3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma.
     J Gastroenterol Hepatol. 2020 Nov 20. doi: 10.1111/jgh.15319.
     PubMed     Abstract available
     
     
     
131. KIM S, Kim KH, Kim BK, Park JY, et al
     Lenvatinib is independently associated with the reduced risk of progressive disease when compared to sorafenib in patients with advanced hepatocellular carcinoma.
     J Gastroenterol Hepatol. 2020 Nov 20. doi: 10.1111/jgh.15355.
     PubMed     Abstract available
     
     
     
132. CRESPO J, Fernandez Carrillo C, Iruzubieta P, Hernandez-Conde M, et al
     MASSIVE IMPACT OF COVID-19 PANDEMIC ON GASTROENTEROLOGY AND HEPATOLOGY DEPARTMENTS AND DOCTORS IN SPAIN.
     J Gastroenterol Hepatol. 2020 Nov 12. doi: 10.1111/jgh.15340.
     PubMed     Abstract available
     
     
     
133. HIRAOKA A, Kumada T, Kariyama K, Tada T, et al
     Clinical importance of muscle volume in lenvatinib for hepatocellular carcinoma: analysis adjusted with inverse probability weighting.
     J Gastroenterol Hepatol. 2020 Nov 10. doi: 10.1111/jgh.15336.
     PubMed     Abstract available
     
     
     
134. CHEN H, Sung JJ
     Potentials of AI in Medical Image Analysis in Gastroenterology and Hepatology.
     J Gastroenterol Hepatol. 2020 Nov 3. doi: 10.1111/jgh.15327.
     PubMed     Abstract available
     
     
     October 2020
135. WANG J, Ning J, Qian X, Zhang T, et al
     Deletion of Golgi protein73 delayed hepatocytes proliferation of mouse in the early stages of liver regeneration.
     J Gastroenterol Hepatol. 2020 Oct 29. doi: 10.1111/jgh.15315.
     PubMed     Abstract available
     
     
     
136. TOSHIMA T, Yoshizumi T, Harada N, Ikegami T, et al
     Hepatobiliary and Pancreatic: A new strategy of endoscopic ultrasonography-guided internal drainage for a refractory hepatic abscess after liver transplantation.
     J Gastroenterol Hepatol. 2020 Oct 7. doi: 10.1111/jgh.15216.
     PubMed    
     
     
     
137. GAO F, Huang JF, Zheng KI, Pan XY, et al
     Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.
     J Gastroenterol Hepatol. 2020;35:1804-1812.
     PubMed     Abstract available
     
     
     
138. WIJARNPREECHA K, Scribani M, Raymond P, Harnois DM, et al
     PNPLA3 gene polymorphism and overall and cardiovascular mortality in the United States.
     J Gastroenterol Hepatol. 2020;35:1789-1794.
     PubMed     Abstract available
     
     
     
139. KITAGATAYA T, Suda G, Nagashima K, Katsurada T, et al
     Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
     J Gastroenterol Hepatol. 2020;35:1782-1788.
     PubMed     Abstract available
     
     
     
140. SALMAN AA, Sultan AAEA, Abdallah A, Abdelsalam A, et al
     Effect of weight loss induced by laparoscopic sleeve gastrectomy on liver histology and serum adipokine levels.
     J Gastroenterol Hepatol. 2020;35:1769-1773.
     PubMed     Abstract available
     
     
     
141. YANG J, Sontag D, Gong Y, Minuk GY, et al
     Enhanced Gemcitabine Cytotoxicity with Knockdown of Multidrug Resistance Protein Genes in Human Cholangiocarcinoma Cell Lines.
     J Gastroenterol Hepatol. 2020 Oct 1. doi: 10.1111/jgh.15289.
     PubMed     Abstract available
     
     
     September 2020
142. NAKAJIMA T, Karino Y, Hige S, Suii H, et al
     Factors affecting the recovery of hepatic reserve after sustained virologic response by direct-acting antiviral agents in chronic HCV-infected patients.
     J Gastroenterol Hepatol. 2020 Sep 29. doi: 10.1111/jgh.15280.
     PubMed     Abstract available
     
     
     
143. YOKOYAMA K, Irie M, Tsuchiya N, Yamauchi E, et al
     Irsogladine maleate alters expression of a tight junction protein in portal hypertensive gastropathy.
     J Gastroenterol Hepatol. 2020 Sep 14. doi: 10.1111/jgh.15259.
     PubMed     Abstract available
     
     
     
144. SANDI BB, Leao GS, de Mattos AA, de Mattos AZ, et al
     Long-term albumin administration in patients with cirrhosis and ascites: a meta-analysis of randomized controlled trials.
     J Gastroenterol Hepatol. 2020 Sep 10. doi: 10.1111/jgh.15253.
     PubMed     Abstract available
     
     
     
145. PARK S, Jung J, Cho B, Kim SY, et al
     In reply to Huo et al.: Treating Small Hepatocellular Carcinoma: Stereotactic Body Radiation Therapy Versus Radiofrequency Ablation.
     J Gastroenterol Hepatol. 2020 Sep 9. doi: 10.1111/jgh.15250.
     PubMed    
     
     
     
146. PYO JH, Kim TJ, Lee H, Choi SC, et al
     Proton Pump Inhibitors Use and the Risk of Fatty Liver Disease; A Nationwide Cohort Study.
     J Gastroenterol Hepatol. 2020 Sep 4. doi: 10.1111/jgh.15236.
     PubMed     Abstract available
     
     
     
147. YOU MW, Kim KW, Shim JJ, Pyo J, et al
     Impact of liver-stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: A systematic review and time-to-event meta-analysis.
     J Gastroenterol Hepatol. 2020 Sep 1. doi: 10.1111/jgh.15243.
     PubMed     Abstract available
     
     
     
148. SHIMIZU Y, Tamura T, Kemmochi A, Owada Y, et al
     Oxidative stress and LXR agonist induce hepatocellular carcinoma in NASH model.
     J Gastroenterol Hepatol. 2020 Sep 1. doi: 10.1111/jgh.15239.
     PubMed     Abstract available
     
     
     
149. KOGISO T, Hashimoto E
     Are low triglyceride levels the cause or an outcome of advanced liver fibrosis in elderly patients with nonalcoholic fatty liver disease?
     J Gastroenterol Hepatol. 2020;35:1459-1460.
     PubMed    
     
     
     
150. CHEN TP, Lai M, Lin WY, Huang KC, et al
     Metabolic profiles and fibrosis of nonalcoholic fatty liver disease in the elderly: A community-based study.
     J Gastroenterol Hepatol. 2020;35:1636-1643.
     PubMed     Abstract available
     
     
     
151. ADAMS LA, Roberts SK, Strasser SI, Mahady SE, et al
     Nonalcoholic fatty liver disease burden: Australia, 2019-2030.
     J Gastroenterol Hepatol. 2020;35:1628-1635.
     PubMed     Abstract available
     
     
     August 2020
152. DEL HOYO J, Lopez-Munoz P, Fernandez-de la Varga M, Garrido-Marin A, et al
     Hepatobiliary and Pancreatic: A fatal case of extensive splanchnic vein thrombosis in a patient with Covid-19.
     J Gastroenterol Hepatol. 2020 Aug 24. doi: 10.1111/jgh.15174.
     PubMed    
     
     
     
153. HIRAI M, Kinugasa H, Nouso K, Yamamoto S, et al
     Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA.
     J Gastroenterol Hepatol. 2020 Aug 24. doi: 10.1111/jgh.15227.
     PubMed     Abstract available
     
     
     
154. EFE C, Torgutalp M, Henriksson I, Alalkim F, et al
     Extrahepatic autoimmune diseases in primary biliary cholangitis: prevalence, significance for clinical presentation and disease outcome.
     J Gastroenterol Hepatol. 2020 Aug 13. doi: 10.1111/jgh.15214.
     PubMed     Abstract available
     
     
     
155. CHUAH KH, Lai LL, Vethakkan SR, Nik Mustapha NR, et al
     Liver stiffness measurement in non-alcoholic fatty liver disease: Two is better than one.
     J Gastroenterol Hepatol. 2020;35:1404-1411.
     PubMed     Abstract available
     
     
     
156. SHARMA A, Goel A, Moses V, Keshava SN, et al
     Anticoagulating Budd-Chiari syndrome patients presenting with variceal bleed: A retrospective study.
     J Gastroenterol Hepatol. 2020;35:1397-1403.
     PubMed     Abstract available
     
     
     July 2020
157. HUO TI, Ho SY, Liu PH
     Is CT-enhanced clinical significant portal hypertension surrogate an authentic prognostic predictor for surgical hepatocellular carcinoma?
     J Gastroenterol Hepatol. 2020 Jul 27. doi: 10.1111/jgh.15203.
     PubMed    
     
     
     
158. KHAN A, Maheshwari S, Gupta K, Naseem K, et al
     Rate, Reasons, Predictors, and Burden of Readmissions After Transjugular Intrahepatic Portosystemic Shunt Placement.
     J Gastroenterol Hepatol. 2020 Jul 25. doi: 10.1111/jgh.15194.
     PubMed     Abstract available
     
     
     
159. KIM KS, Kwon HM, Jung KW, Sang BH, et al
     Markedly prolonged QTc interval in end-stage liver disease and risk of 30-day cardiovascular event after liver transplant.
     J Gastroenterol Hepatol. 2020 Jul 13. doi: 10.1111/jgh.15179.
     PubMed     Abstract available
     
     
     
160. CHEN A, Li S, Yao Z, Hu J, et al
     Adjuvant Transarterial Chemoembolization to Sorafenib in Unresectable Hepatocellular Carcinoma: A Meta-Analysis.
     J Gastroenterol Hepatol. 2020 Jul 11. doi: 10.1111/jgh.15180.
     PubMed     Abstract available
     
     
     
161. SHANKER MD, Liu HY, Lee YY, Stuart KA, et al
     Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium.
     J Gastroenterol Hepatol. 2020 Jul 6. doi: 10.1111/jgh.15175.
     PubMed     Abstract available
     
     
     
162. LAUBE R, Sabih AH, Strasser SI, Lim L, et al
     Palliative Care in Hepatocellular Carcinoma.
     J Gastroenterol Hepatol. 2020 Jul 6. doi: 10.1111/jgh.15169.
     PubMed     Abstract available
     
     
     
163. YAMAMURA S, Nakano D, Hashida R, Tsutsumi T, et al
     Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
     J Gastroenterol Hepatol. 2020 Jul 6. doi: 10.1111/jgh.15172.
     PubMed     Abstract available
     
     
     
164. FAN J, Wang Q, Luo B, Chen H, et al
     Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: A hospital-based observational study.
     J Gastroenterol Hepatol. 2020;35:1215-1222.
     PubMed     Abstract available
     
     
     June 2020
165. TANG RSY, Kyaw MH, Teoh AYB, Lui RNS, et al
     EUS guided cyanoacrylate injection to prevent rebleeding in hepatocellular carcinoma patients with variceal hemorrhage.
     J Gastroenterol Hepatol. 2020 Jun 30. doi: 10.1111/jgh.15168.
     PubMed     Abstract available
     
     
     
166. TAN EZ, Lai LL, Vethakkan SR, Nik Mustapha NR, et al
     Modest alcohol intake is not associated with significant hepatic steatosis nor more severe liver disease among patient with diabetes mellitus.
     J Gastroenterol Hepatol. 2020 Jun 24. doi: 10.1111/jgh.15160.
     PubMed     Abstract available
     
     
     
167. BRAHMANIA M, Wiskar K, Walley KR, Celi LA, et al
     Lower household income is associated with an increased risk of hospital readmission in patients with decompensated cirrhosis.
     J Gastroenterol Hepatol. 2020 Jun 20. doi: 10.1111/jgh.15153.
     PubMed     Abstract available
     
     
     
168. SAKAI N, Yoshitomi H, Furukawa K, Takayashiki T, et al
     Outcome of interventional radiology for delayed postoperative hemorrhage in hepatobiliary and pancreatic surgery.
     J Gastroenterol Hepatol. 2020 Jun 11. doi: 10.1111/jgh.15140.
     PubMed     Abstract available
     
     
     
169. CAO DB, Wang YS
     Gastrointestinal: Intrahepatic periportal masses with uncommon computed tomography patterns: Hepatic extramedullary hematopoiesis of primary mylofibrosis.
     J Gastroenterol Hepatol. 2020 Jun 7. doi: 10.1111/jgh.15069.
     PubMed    
     
     
     
170. GURKA MJ, Mack JA, Chi X, DeBoer MD, et al
     Use of Metabolic Syndrome Severity to Assess Treatment with Vitamin-E and Pioglitazone for Non-alcoholic Steatohepatitis.
     J Gastroenterol Hepatol. 2020 Jun 7. doi: 10.1111/jgh.15131.
     PubMed     Abstract available
     
     
     
171. GOMEZ CIFUENTES JD, Sparkman J, Choi K, Sealock RJ, et al
     Regarding: Lui RN, Wong SH, Sanchez-Luna SA, et al. Overview of guidance for endoscopy during the coronavirus disease 2019 pandemic. J Gastroenterol Hepatol. 2020;35(5):749-759. doi:10.1111/jgh.15053.
     J Gastroenterol Hepatol. 2020 Jun 5. doi: 10.1111/jgh.15129.
     PubMed    
     
     
     
172. LEE HW, Ahn SH
     How do genetic variants affect our interpretation of non-invasive tests for non-alcoholic fatty liver disease?
     J Gastroenterol Hepatol. 2020;35:915-916.
     PubMed    
     
     
     
173. SHIN SK, Kim KO, Kim SH, Kwon OS, et al
     Exogenous 8-hydroxydeoxyguanosine ameliorates liver fibrosis through the inhibition of Rac1-NADPH oxidase signaling.
     J Gastroenterol Hepatol. 2020;35:1078-1087.
     PubMed     Abstract available
     
     
     
174. NGUYEN TH, Wardell R, Chitturi S, Teoh N, et al
     When the liver gets stiff, the tough get moving.
     J Gastroenterol Hepatol. 2020;35:953-959.
     PubMed     Abstract available
     
     
     
175. SAWADA K, Hayashi H, Nakajima S, Hasebe T, et al
     Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor.
     J Gastroenterol Hepatol. 2020;35:1042-1048.
     PubMed     Abstract available
     
     
     
176. LIU WY, Zheng KI, Pan XY, Ma HL, et al
     Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease.
     J Gastroenterol Hepatol. 2020;35:1057-1064.
     PubMed     Abstract available
     
     
     
177. CHEN H, He C, Lv Y, Fan J, et al
     Long-term results of variceal bleeding management in 302 patients with chronic extrahepatic portal vein obstruction.
     J Gastroenterol Hepatol. 2020;35:1049-1056.
     PubMed     Abstract available
     
     
     May 2020
178. HUO TI, Liu PH, Ho SY
     Treating small hepatocellular carcinoma: Stereotactic body radiation therapy vs RFA.
     J Gastroenterol Hepatol. 2020 May 31. doi: 10.1111/jgh.15126.
     PubMed    
     
     
     
179. LI Y, He HC, Zhou DL, Liu Q, et al
     Associations between lncRNA-related polymorphisms and hepatocellular carcinoma risk: A two-stage case-control study.
     J Gastroenterol Hepatol. 2020 May 26. doi: 10.1111/jgh.15118.
     PubMed     Abstract available
     
     
     
180. LEE DH, Chung JW, Joo I, Suh KS, et al
     Varices on Computed Tomography Could Predict Survival after Hepatic Resection in Patients with Single Hepatocellular Carcinoma.
     J Gastroenterol Hepatol. 2020 May 26. doi: 10.1111/jgh.15117.
     PubMed     Abstract available
     
     
     
181. XU X, Lei Y, Zhou H, Guo Y, et al
     beta-Arrestin1 involves in hepatocellular carcinoma metastasis via ERK mediated epithelial-mesenchymal transition.
     J Gastroenterol Hepatol. 2020 May 22. doi: 10.1111/jgh.15115.
     PubMed     Abstract available
     
     
     
182. MA KW, So H, Cho DH, Oh JS, et al
     Durability and outcome of EUS-guided hepaticoduodenostomy using a fully covered metal stent for segregated right intrahepatic duct dilatation.
     J Gastroenterol Hepatol. 2020 May 4. doi: 10.1111/jgh.15089.
     PubMed     Abstract available
     
     
     
183. KOBAYASHI T, Kanno K, Nguyen PT, Sugiyama A, et al
     Periostin antisense oligonucleotide prevents hepatic steatosis and fibrosis in a mouse model of nonalcoholic steatohepatitis.
     J Gastroenterol Hepatol. 2020 May 4. doi: 10.1111/jgh.15088.
     PubMed     Abstract available
     
     
     
184. YANG C, Yang H, Deng S, Zhang Y, et al
     Hepatobiliary and Pancreatic: Hepatic cystadenoma mimics hepatic cystic echinococcsis.
     J Gastroenterol Hepatol. 2020 May 3. doi: 10.1111/jgh.15044.
     PubMed    
     
     
     
185. WARRILLOW S, Fisher C, Tibballs H, Bailey M, et al
     Coagulation abnormalities, bleeding, thrombosis, and management of patients with acute liver failure in Australia and New Zealand.
     J Gastroenterol Hepatol. 2020;35:846-854.
     PubMed     Abstract available
     
     
     
186. SINN DH, Kang D, Chang Y, Ryu S, et al
     Non-alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study.
     J Gastroenterol Hepatol. 2020;35:833-839.
     PubMed     Abstract available
     
     
     April 2020
187. YIP TC, Wong GL, Chan HL, Tse YK, et al
     Elevated testosterone increases risk of hepatocellular carcinoma in men with chronic hepatitis B and diabetes mellitus.
     J Gastroenterol Hepatol. 2020 Apr 28. doi: 10.1111/jgh.15079.
     PubMed     Abstract available
     
     
     
188. TSENG CH, Tseng CM, Wu JL, Hsu YC, et al
     Magnitude of and Prediction for Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Taking Entecavir or Tenofovir Therapy: A Systematic Review.
     J Gastroenterol Hepatol. 2020 Apr 28. doi: 10.1111/jgh.15078.
     PubMed     Abstract available
     
     
     
189. MAZIDI M, Ofori-Asenso R, Kengne AP
     Dietary Patterns Are Associated with Likelihood of Hepatic Steatosis among US Adults.
     J Gastroenterol Hepatol. 2020 Apr 26. doi: 10.1111/jgh.15076.
     PubMed     Abstract available
     
     
     
190. WANG Y, Shen J, Feng S, Liang R, et al
     Hepatic Resection versus Transarterial Chemoembolization in Infiltrative Hepatocellular Carcinoma: A Multicenter Study.
     J Gastroenterol Hepatol. 2020 Apr 4. doi: 10.1111/jgh.15060.
     PubMed     Abstract available
     
     
     
191. OGURA T, Nishioka N, Ueno S, Yamada M, et al
     Guidewire insertion under transluminal cholangioscopy guidance for a hepaticojejunostomy stricture resembling a pinhole (with video).
     J Gastroenterol Hepatol. 2020 Apr 4. doi: 10.1111/jgh.15050.
     PubMed    
     
     
     
192. SHARMA S, Kumar R, Rout G, Gamanagatti SR, et al
     Dabigatran as an oral anticoagulant in patients with Budd-Chiari syndrome post-percutaneous endovascular intervention.
     J Gastroenterol Hepatol. 2020;35:654-662.
     PubMed     Abstract available
     
     
     March 2020
193. KIM JH, Kang SH, Lee M, Choi HS, et al
     Improved Detection of Hepatocellular Carcinoma by Dynamic CT in Cirrhotic Patients With Chronic Hepatitis B: A Multi-Center Study.
     J Gastroenterol Hepatol. 2020 Mar 28. doi: 10.1111/jgh.15046.
     PubMed     Abstract available
     
     
     
194. YE L, Yu Y, Zhao Y
     Icariin-induced miR-875-5p attenuates epithelial-mesenchymal transition by targeting hedgehog signaling in liver fibrosis.
     J Gastroenterol Hepatol. 2020;35:482-491.
     PubMed     Abstract available
     
     
     February 2020
195. KHOO S, Wong VW, Goh GB, Fan J, et al
     Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease.
     J Gastroenterol Hepatol. 2020;35:320-325.
     PubMed     Abstract available
     
     
     
196. SAHLMAN P, Nissinen M, Puukka P, Jula A, et al
     Genetic and lifestyle risk factors for advanced liver disease among men and women.
     J Gastroenterol Hepatol. 2020;35:291-298.
     PubMed     Abstract available
     
     
     
197. HIROOKA M, Ochi H, Hiraoka A, Koizumi Y, et al
     Role of severe thrombocytopenia in preventing platelet count recovery in thrombocytopenic patients with chronic liver disease.
     J Gastroenterol Hepatol. 2020;35:299-304.
     PubMed     Abstract available
     
     
     January 2020
198. LEONG WL, Lai LL, Nik Mustapha NR, Vijayananthan A, et al
     Comparing point shear wave elastography (ElastPQ) and transient elastography for diagnosis of fibrosis stage in non-alcoholic fatty liver disease.
     J Gastroenterol Hepatol. 2020;35:135-141.
     PubMed     Abstract available
     
     
     
199. CHUNG GE, Heo NJ, Kim D, Kwak MS, et al
     Association between advanced fibrosis in fatty liver disease and overall mortality based on body fat distribution.
     J Gastroenterol Hepatol. 2020;35:90-96.
     PubMed     Abstract available
     
     
     November 2019
200. JOSHITA S, Yamashita Y, Sugiura A, Uehara T, et al
     Clinical utility of FibroScan as a non-invasive diagnostic test for primary biliary cholangitis.
     J Gastroenterol Hepatol. 2019 Nov 14. doi: 10.1111/jgh.14929.
     PubMed     Abstract available
     
     
     
201. FRENCH J, van der Mei I, Simpson S Jr, Ng J, et al
     Increasing Prevalence of Primary Biliary Cholangitis in Victoria, Australia.
     J Gastroenterol Hepatol. 2019 Nov 6. doi: 10.1111/jgh.14924.
     PubMed     Abstract available
     
     
     
202. TAKANO K, Saeki C, Oikawa T, Hidaka A, et al
     IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate.
     J Gastroenterol Hepatol. 2019 Nov 1. doi: 10.1111/jgh.14900.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: